NurExone Biologic Inc. (TSXV: NRX | OTCQB: NRXBF | FSE: J90), a biotechnology company developing exosome-based regenerative therapies, has announced the voting results from its annual general and special meeting held on September 15, 2026. Shareholders approved all resolutions put forward, including granting the Board discretionary authority to implement a share consolidation of up to 30:1. The company also disclosed a new capital markets consulting agreement with U.S.-based Acorn Management Partners, positioning the announcement as a potential step toward a future U.S. exchange listing.

Key Points

  • NurExone Biologic Inc. (TSXV: NRX | OTCQB: NRXBF | FSE: J90) held its annual general and special meeting on September 15, 2026
  • Shareholders approved a consolidation resolution granting the Board authority to consolidate shares at up to 30:1 within 36 months, subject to TSXV acceptance
  • A 12-month investor relations agreement with Acorn Management Partners carries maximum aggregate base fees of US$180,000
  • Investors may be watching whether the Board elects to proceed with consolidation and any U.S. exchange listing developments

Share Consolidation Authority Approved by Required Supermajority

The consolidation resolution received approval from 97.61% of votes cast at the meeting, surpassing the required two-thirds supermajority threshold. The authority permits the Board, at its sole discretion, to consolidate up to 30 pre-consolidation shares into one post-consolidation share at any point within 36 months of the resolution's approval, subject to TSXV acceptance. Shareholder approval does not obligate the Board to proceed, and the Board retains the right to revoke the resolution or elect not to implement the consolidation. Chairman Yoram Drucker stated the approval provides flexibility to evaluate market conditions, trading performance, and potential U.S. exchange-listing requirements before making any determination.

Director Elections and Routine Resolutions Carried with Strong Support

All five director nominees were re-elected with strong shareholder backing. Yoram Drucker and Eyal Gabbai each received approximately 99.96% of votes in favour. The meeting also saw Shareholders reappoint Ziv Haft, CPA (Isr.), a BDO member firm, as auditor with 99.95% approval, and re-approve the company's amended and restated omnibus equity incentive plan with 99.17% of eligible votes. A total of 32,963,581 shares were represented at the meeting, equating to 34.90% of issued and outstanding shares as at the record date.

Acorn Management Partners Engaged for U.S. Capital Markets Visibility

NurExone disclosed a non-exclusive, cash-only professional relations and capital markets consulting agreement with Acorn Management Partners, L.L.C., based in Alpharetta, Georgia. Subject to TSXV acceptance, the agreement runs for 12 months ending September 14, 2027, with maximum aggregate base fees of US$180,000. Acorn will not receive securities as compensation and has confirmed it holds no securities in the company. Services are directed at licensed brokers and U.S. investment professionals and are intended to communicate NurExone's publicly disclosed investment thesis rather than provide investment recommendations or price targets.